Biolinerx announces clinical trial agreement with st. jude children's research hospital, inc. to evaluate motixafortide for cd34+ hematopoietic stem cell (hsc) mobilization for gene therapy applications in sickle cell disease (scd)

- investigator-initiated study includes leading researchers in scd gene therapy clinical development from st. jude children's research hospital, inc. and two other clinical sites -   - new trial to expand ongoing clinical research of motixafortide for mobilization of hscs in patients with scd - tel aviv, israel , may 30, 2024 /prnewswire/ -- biolinerx ltd. (nasdaq: blrx) (tase: blrx), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center phase 1 clinical trial sponsored  by st. jude children's research hospital, inc. to evaluate motixafortide for the mobilization of cd34+ hematopoietic stem cells (hscs) used in the development of gene therapies for patients with sickle cell disease (scd).
HSC Ratings Summary
HSC Quant Ranking